Recombinant Rod Domain of Vimentin Reduces SARS-CoV-2 Viral Replication by Blocking Spike Protein–ACE2 Interactions
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25052477 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Fong Wilson Lam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: COVID-19, Pneumonia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH/NHLBI, Michael E. DeBakey Veterans Affairs Medical Center Seed Award.
Abstract (Originalsprache)
Although the SARS-CoV-2 vaccination is the primary preventive intervention, there are still few antiviral therapies available, with current drugs decreasing viral replication once the virus is intracellular. Adding novel drugs to target additional points in the viral life cycle is paramount in preventing future pandemics. The purpose of this study was to create and test a novel protein to decrease SARS-CoV-2 replication. We created the recombinant rod domain of vimentin (rhRod) in E. coli and used biolayer interferometry to measure its affinity to the SARS-CoV-2 S1S2 spike protein and the ability to block the SARS-CoV-2–ACE2 interaction. We performed plaque assays to measure rhRod’s effect on SARS-CoV-2 replication in Vero E6 cells. Finally, we measured lung inflammation in SARS-CoV-2-exposed K18-hACE transgenic mice given intranasal and intraperitoneal rhRod. We found that rhRod has a high affinity for the S1S2 protein with a strong ability to block S1S2–ACE2 interactions. The daily addition of rhRod decreased viral replication in Vero E6 cells starting at 48 h at concentrations >1 µM. Finally, SARS-CoV-2-infected mice receiving rhRod had decreased lung inflammation compared to mock-treated animals. Based on our data, rhRod decreases SARS-CoV-2 replication in vitro and lung inflammation in vivo. Future studies will need to evaluate the protective effects of rhRod against additional viral variants and identify the optimal dosing scheme that both prevents viral replication and host lung injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
- Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA.
- Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.
- William T. Shearer Center for Human Immunobiology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX 77030, USA.
ORCID-Profile: Fong Wilson Lam
Förderung
- NIGMS NIH HHS
- NIH/NHLBI
- Michael E. DeBakey Veterans Affairs Medical Center Seed Award
- Department of Pediatrics, Division of Tropical Medicine at Baylor College of Medicine and Texas Children’s Hospital
Zitieren
APA
Lam, F. W., Brown, C. A., & Ronca, S. E. (2024). Recombinant Rod Domain of Vimentin Reduces SARS-CoV-2 Viral Replication by Blocking Spike Protein–ACE2 Interactions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052477
Vancouver
Lam FW, Brown CA, Ronca SE. Recombinant Rod Domain of Vimentin Reduces SARS-CoV-2 Viral Replication by Blocking Spike Protein–ACE2 Interactions. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052477
BibTeX
@article{Lam2024,
author = {Lam, Fong Wilson and Brown, Cameron August and Ronca, Shannon Elizabeth},
title = {Recombinant Rod Domain of Vimentin Reduces SARS-CoV-2 Viral Replication by Blocking Spike Protein–ACE2 Interactions},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25052477}
}
EUVIMED